News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
789,242 Results
Type
Article (55183)
Company Profile (265)
Press Release (733786)
Multimedia
Podcasts (230)
Webinars (25)
Section
Business (245313)
Career Advice (2853)
Deals (38408)
Drug Delivery (216)
Drug Development (86021)
Employer Resources (170)
FDA (17578)
Job Trends (16018)
News (366009)
Policy (35986)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (1)
2027 BioCapital Standard (4)
2027 BioMidwest Digital (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (3)
2027 Bio NC Standard (3)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (9)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (6)
2027 Genetown Elite (4)
2027 Genetown Premier (1)
2027 Genetown Standard (11)
2027 Pharm Country Digital (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (10)
40 Under 40 (1)
Academia (2943)
Accelerated approval (71)
ADA (53)
Adcomms (38)
Allergies (226)
Alliances (52770)
ALS (278)
Alzheimer's disease (2067)
Antibody-drug conjugate (ADC) (730)
Approvals (18195)
Artificial intelligence (1035)
ASCO (334)
Autoimmune disease (487)
Automation (79)
Bankruptcy (391)
Belgium (35)
Best Places to Work (12024)
BIO (72)
Biologics (85)
BIOSECURE Act (22)
Biosimilars (298)
BioSpace Insights (222)
Biotechnology (173)
Bispecific (45)
Bladder cancer (238)
Brain cancer (97)
Breast cancer (934)
Cancer (7604)
Cardiovascular disease (636)
Career advice (2435)
Career pathing (54)
CAR-T (431)
CDC (73)
CDMO (209)
Celiac Disease (7)
Cell-line development (2)
Cell therapy (1166)
Cervical cancer (66)
Clinical research (76178)
Collaboration (2736)
Commercialization (54)
Company closure (6)
Compensation (1831)
Complete response letters (123)
COVID-19 (2947)
CRISPR (145)
CRO (3)
C-suite (1605)
Cystic fibrosis (175)
Data (10495)
Decentralized trials (4)
Denatured (100)
Depression (216)
Dermatology (184)
Diabetes (816)
Diagnostics (7597)
Digital health (79)
Diversity (11)
Diversity, equity & inclusion (44)
Drug discovery (508)
Drug pricing (238)
Drug shortages (35)
Duchenne muscular dystrophy (365)
Earnings (95831)
Editorial (78)
Employer branding (21)
Employer resources (154)
ESMO (418)
Events (128063)
Executive appointments (1303)
Eye disease (16)
FDA (22504)
Fibrodysplasia Ossificans Progressiva (16)
Fragile X (6)
Friedreich's ataxia (28)
Frontotemporal dementia (42)
Funding (2276)
Gene editing (302)
Generative AI (95)
Gene therapy (927)
GLP-1 (1314)
Government (5175)
Grass and pollen (7)
Guidances (435)
Healthcare (20057)
Hematology (199)
HIV (115)
Huntington's disease (87)
Idiopathic pulmonary fibrosis (14)
IgA nephropathy (152)
Immunology and inflammation (395)
Immuno-oncology (153)
Indications (285)
Infectious disease (3384)
Inflammatory bowel disease (271)
Inflation Reduction Act (15)
Influenza (158)
Intellectual property (372)
Interviews (498)
IPO (17395)
IRA (55)
Job creations (4310)
Job search strategy (2015)
JPM (63)
Kidney cancer (28)
Kidney disease (165)
Labor market (115)
Layoffs (649)
Leadership (61)
Legal (9051)
Licensing (98)
Liver cancer (113)
Longevity (55)
Lung cancer (1059)
Lung diease (21)
Lymphoma (536)
Machine learning (75)
Management (62)
Manufacturing (1538)
Marketing (33)
MASH (241)
Medical affairs (5)
Medical device (14626)
Medtech (14938)
Mergers & acquisitions (22542)
Metabolic disorders (2017)
mRNA (315)
Multiple sclerosis (251)
Multispecific (6)
NASH (23)
Netherlands (28)
Neurodegenerative disease (586)
Neuropsychiatric disorders (145)
Neuroscience (4158)
Neurotech (3)
NextGen: Class of 2026 (6979)
Non-profit (4777)
Now hiring (81)
Obesity (941)
Opinion (383)
Ovarian cancer (292)
Pain (343)
Pancreatic cancer (434)
Parkinson's disease (476)
Partnered (41)
Patents (780)
Patient advocacy (5)
Patient recruitment (970)
Patient selection (96)
Peanut (76)
People (62669)
Peptides (30)
Pharmaceutical (58)
Pharmacy benefit managers (40)
Phase 1 (23638)
Phase 2 (33377)
Phase 3 (25128)
Pipeline (13618)
Policy (399)
Postmarket research (2781)
Preclinical (10186)
Press Release (70)
Prostate cancer (398)
Psychedelics (89)
Radioligand (3)
Radiopharmaceuticals (421)
Rare diseases (1537)
Real estate (6345)
Recruiting (68)
Regenerative medicine (26)
Regulatory (29077)
Reports (64)
Research institute (2631)
Resumes & cover letters (461)
Rett syndrome (59)
RNA editing (37)
RSV (103)
Schizophrenia (224)
Series A (400)
Series B (276)
Service/supplier (6)
Sickle cell disease (140)
Special edition (36)
Spinal muscular atrophy (191)
Sponsored (58)
Startups (4021)
State (2)
Stem cells (6)
Stomach cancer (23)
Substance use disorders (21)
Supply chain (162)
Switzerland (9)
Tariffs (101)
Tax incentives (1)
The Weekly (128)
Vaccines (1335)
Venture capital (167)
Weight loss (620)
Wet AMD (7)
Women's health (182)
Women in leadership (1)
Worklife (22)
Date
Last 7 days (813)
Last 30 days (2863)
Last 365 days (32224)
2026 (27054)
2025 (31739)
2024 (36479)
2023 (41253)
2022 (52587)
2021 (57134)
2020 (55791)
2019 (48546)
2018 (36950)
2017 (34209)
2016 (34014)
2015 (39960)
2014 (33693)
2013 (29310)
2012 (31141)
2011 (31461)
2010 (29330)
Location
Africa (987)
Alabama (108)
Alaska (6)
Arizona (448)
Arkansas (17)
Asia (46038)
Australia (7548)
California (16351)
Canada (4546)
China (1921)
Colorado (727)
Connecticut (707)
Delaware (486)
Europe (101199)
Florida (2486)
Georgia (534)
Hawaii (5)
Idaho (68)
Illinois (1354)
India (146)
Indiana (747)
Iowa (34)
Japan (754)
Kansas (149)
Kentucky (63)
Louisiana (67)
Maine (96)
Maryland (1938)
Massachusetts (11718)
Michigan (411)
Minnesota (869)
Mississippi (6)
Missouri (171)
Montana (33)
Nebraska (30)
Nevada (185)
New Hampshire (90)
New Jersey (4302)
New Mexico (36)
New York (4305)
North Carolina (2055)
North Dakota (12)
Northern California (8409)
Ohio (495)
Oklahoma (29)
Oregon (51)
Pennsylvania (3144)
Puerto Rico (36)
Rhode Island (59)
South America (1333)
South Carolina (98)
South Dakota (1)
Southern California (6545)
Tennessee (275)
Texas (2699)
United States (57639)
Utah (497)
Vermont (2)
Virginia (423)
Washington D.C. (84)
Washington State (1307)
West Virginia (4)
Wisconsin (187)
Wyoming (6)
789,242 Results for "kai pharmaceuticals inc acquired by amgen".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lung cancer
ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
When used alongside AstraZeneca’s Imfinzi, the bispecific T cell engager Imdelltra extended survival by eight months versus Imfinzi alone in Phase 3 study testing the combo in a first-line maintenance setting—a potentially “practice-changing” outcome, according to Truist Securities.
October 26, 2026
·
4 min read
·
Tristan Manalac
Regulatory
Amgen continues to defend Tavneos as global regulatory pressure mounts
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx.
July 10, 2026
·
4 min read
·
Nick Paul Taylor
Regulatory
Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing
CSL Vifor holds the marketing authorization for Tavneos in the U.K., where the drug is marketed as Avacopan Vifor. It continues to be sold on the U.S. market by Amgen despite concerns raised by the FDA.
September 2, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis win
Even without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for Dupixent in eosinophilic esophagitis.
August 28, 2026
·
2 min read
·
Tristan Manalac
Business
Amgen hit with cybersecurity breach, patient data affected
The hack is unlikely to affect Amgen’s financial reporting and other operations, nor does the pharma expect its ability to meet patient needs will be compromised.
August 3, 2026
·
2 min read
·
Tristan Manalac
Press Releases
PostEra’s Fertility programs acquired by EMD Serono, Inc.
September 9, 2026
·
2 min read
Regulatory
Pressure piles on Amgen after EU pulls Tavneos, flags ‘serious breaches’ in pivotal study
Sponsors of the pivotal study behind Amgen’s rare disease drug Tavneos saw unblinded findings for the drug and re-adjudicated data from nine patients to make the drug seem effective, according to European regulators.
August 14, 2026
·
2 min read
·
Tristan Manalac
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
The vibe at BIO 2026 in San Diego last week was overwhelmingly positive, with attendees observing noticeable changes at the FDA and an uptick in dealmaking and IPOs. Plus, a top medical journal this week retracted a pivotal study for Amgen’s rare disease drug Tavneos, which has been in the FDA’s crosshairs since January.
July 1, 2026
·
2 min read
·
Jef Akst
Regulatory
Amgen’s Tavneos troubles continue as
NEJM
retracts pivotal publication
Earlier this year, Amgen refused the FDA’s request to withdraw Tavneos from the market. Now, two researchers who participated in the original study to support the drug’s approval claim they did not know the primary endpoint was readjudicated after the study was unblinded.
June 30, 2026
·
2 min read
·
Tristan Manalac
Obesity
Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
Amgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future business development will focus on earlier-stage opportunities.
August 5, 2026
·
2 min read
·
Tristan Manalac
1 of 78,925
Next
